Ipamorelin 10mg
99.395% HPLC PurityA selective pentapeptide growth-hormone secretagogue (GHRP).

SKU: PEP-016-10MG
A modified GHRH(1-29) analogue without the Drug Affinity Complex, supplied as a 10mg lyophilised vial. Research use only. Preorder — ships with the first batch.
Read the full description ↓Price includes GST
✓Free shipping on orders over $250 AUD
✓Australia Post tracked — Standard $12.99 / Express $18.99
✓Preorder: dispatched once the next batch arrives, tracked with Australia Post
A selective pentapeptide growth-hormone secretagogue (GHRP).
A stabilised analogue of growth-hormone-releasing hormone (GHRH).
The long-acting GHRH analogue on its own, without the Ipamorelin pairing.
A modified GHRH(1-29) analogue without the Drug Affinity Complex, supplied as a 10mg lyophilised vial.
Also known as modified GRF (1-29), it is studied for GHRH receptor signalling and its short half-life relative to the DAC variant.
This product is currently available to preorder and ships once the first batch has been produced and tested. Strictly for in-vitro laboratory research only.
A modified GHRH(1-29) analogue without the Drug Affinity Complex, supplied as a 10mg lyophilised vial. Also known as modified GRF (1-29), it is studied for GHRH receptor signalling and its short half-life relative to the DAC variant. All use is strictly for in-vitro laboratory research only.
This product is a preorder. It is not held in stock yet and ships with the first batch; you will be emailed when your order is dispatched.
Batch testing documentation is published for each batch once it has been produced and tested. Contact us before ordering if you need it first.
Store lyophilised product at −20°C, protected from light and moisture, and avoid repeated freeze-thaw cycles.
No. CJC-1295 (no DAC) is supplied for in-vitro laboratory research only and is not approved for human consumption or therapeutic use. Scheduling attaches to the substance and changes over time; verify the current status against the TGA Poisons Standard.
CJC-1295 (no DAC) 10mg is sold strictly for in-vitro laboratory and research purposes only. This product is not intended for human consumption, therapeutic use, cosmetic use, or veterinary application. It has not been evaluated by the Therapeutic Goods Administration (TGA) or any other regulatory body for human use. You must be 18 years of age or older to purchase. By purchasing, you confirm that you are a qualified researcher and will use this product in compliance with all applicable Australian laws and regulations.
No questions yet — be the first to ask about this product.
Recent peer-reviewed studies from PubMed related to CJC-1295 (no DAC). Provided for research context — not medical advice.
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Teichman SL, Neale A, Lawrence B, et al. · The Journal of clinical endocrinology and metabolism · 2006
PMID: 16352683
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
Sackmann-Sala L, Ding J, Frohman LA, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009
PMID: 19386527
Advances in the detection of growth hormone releasing hormone synthetic analogs
Memdouh S, Gavrilović I, Ng K, et al. · Drug testing and analysis · 2021
PMID: 34665524
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
Alba M, Fintini D, Sagazio A, et al. · American journal of physiology. Endocrinology and metabolism · 2006
PMID: 16822960
Source: U.S. National Library of Medicine (PubMed). Citations are fetched live and cached; inclusion does not imply endorsement of any therapeutic use.